Back to Search
Start Over
Do somatostatin-analogues have the same impact on postoperative morbidity and pancreatic fistula in patients after pancreaticoduodenectomy and distal pancreatectomy? – A systematic review with meta-analysis of randomized-controlled trials
- Source :
- Pancreatology. 20:1770-1778
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- Postoperative pancreatic fistula/POPF is the most feared complication in pancreatic surgery. Although several systematic reviews investigated the impact of somatostatin analogues on POPF, no stratification was performed regarding type of pancreatic resection (pancreaticoduodenectomy/PD; distal pancreatectomy/DP) and different somatostatin analogues.This study was planed according to the Preferred-Reporting-Items-for-Systematic -Review-and-Meta-Analysis/PRISMA-guidelines. After screening databases for randomized controlled trials/RCT, studies were stratified into pancreatic resection techniques and data were pooled in meta-analyses containing subgroups of octreotide, somatostatin, lanreotide, pasireotide and vapreotide.The meta-analysis of studies with a mixed cohort of patients after pancreatic resection revealed a protective effect of somatostatin analogues for morbidity (RR: 0.71, p .00001) but not for mortality (RR: 1.07, = 0.78) or intra-abdominal abscesses (RR: 1.00, p = 1.00). Moreover, no effect was visible for mortality (RR: 1.57, p = .15), morbidity (RR: 0.87, p = .15) and intra-abdominal abscesses (RR: 0.92, p = .48) after PD. The meta-analysis of patients after PD revealed no impact of somatostatin analogues on POPF (RR: 0.87, p = .19) and clinically relevant POPF (RR: 0.69, p = .30). However, treatment with somatostatin analogues in the mixed cohort showed less POPF (RR: 0.60, p .00001) and clinically relevant POPF (RR: 0.47, p = .02), which was also the case after DP (RR: 0.41, p = .03).Somatostatin analogues did not affect POPF and clinically relevant POPF after PD, but seemed to be associated with less POPF after DP. As no sufficiently powered RCT could be identified by the systematic review, further RCTs are urgently needed to investigate the effect of somatostatin analogues after DP.CRD42018099808.
- Subjects :
- medicine.medical_specialty
Endocrinology, Diabetes and Metabolism
medicine.medical_treatment
Octreotide
Lanreotide
Gastroenterology
Pancreaticoduodenectomy
law.invention
Pancreatic Fistula
03 medical and health sciences
chemistry.chemical_compound
Pancreatectomy
Postoperative Complications
0302 clinical medicine
Randomized controlled trial
law
Internal medicine
medicine
Humans
Postoperative Period
Pancreas
Vapreotide
Hepatology
business.industry
Anastomosis, Surgical
medicine.disease
Pasireotide
Somatostatin
chemistry
Pancreatic fistula
030220 oncology & carcinogenesis
030211 gastroenterology & hepatology
Morbidity
business
medicine.drug
Subjects
Details
- ISSN :
- 14243903 and 42018099
- Volume :
- 20
- Database :
- OpenAIRE
- Journal :
- Pancreatology
- Accession number :
- edsair.doi.dedup.....a506452db4e94e7e0b0aa9fd23e53e15
- Full Text :
- https://doi.org/10.1016/j.pan.2020.10.043